# PACIFIC-8 (NCT05211895)

> A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05211895
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Durvalumab; Domvanalimab; Placebo
- Enrollment: 791
- Primary outcome: Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 5
- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=pacific-8-nct05211895

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05211895", "email": "<work email>"}; the inbox owner confirms by the emailed link.